Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 2/20 | 0.62 |
| ▸ | PLK1 | P53350 | 11/20 | 0.59 |
| ▸ | BRD4 | O60885 | 9/20 | 0.55 |
| ▸ | MAPK7 | Q13164 | 3/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.55 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.55 |
| ▸ | TTK | P33981 | 2/20 | 0.54 |
| ▸ | BRDT | Q58F21 | 8/20 | 0.54 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12558087 | 0.93 | BRD4 (0.59) | RAD52PLK1BRD4MAPK7LRRK2 | |
| SCHEMBL4114036 | 0.91 | RAD52 (0.68) | RAD52PLK1BRD4MAPK7LRRK2 | |
| SCHEMBL1203122 | 0.90 | RAD52 (0.77) | RAD52PLK1BRD4MAPK7LRRK2 | |
| SCHEMBL3667830 | 0.89 | PLK1 (0.59) | RAD52PLK1BRD4MAPK7LRRK2 | |
| SCHEMBL3991428 | 0.89 | RAD52 (0.62) | RAD52PLK1BRD4MAPK7LRRK2 | |
| SCHEMBL1203705 | 0.86 | RAD52 (0.72) | RAD52PLK1BRD4MAPK7LRRK2 | |
| SCHEMBL616568 | 0.86 | LRRK2 (0.69) | PLK1BRD4MAPK7LRRK2DCLK1 | |
| SCHEMBL3538104 | 0.85 | PLK1 (0.60) | RAD52PLK1BRD4MAPK7LRRK2 | |
| SCHEMBL17465879 | 0.85 | TTK (0.75) | PLK1BRD4MAPK7LRRK2DCLK1 | |
| SCHEMBL3994195 | 0.85 | BRD4 (0.52) | RAD52PLK1BRD4MAPK7LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139892-A1 | SUBSTITUTED PYRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-7517873-B2 | Substituted pyrimidodiazepines | HOFFMAN-LA ROCHE INC. (US) | 2009-04-14 | — | — | US | disclosed |
| WO-2008113711-A1 | SUBSTITUTED PYRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | PLK1, CCNI, CDK1 | RAD52 2632/4885PLK1 1/4885BRD4 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.